- Home
- RARE vs VSEC Comparison
RARE vs VSEC Comparison
Compare RARE & VSEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- VSEC
- Stock Information
- Founded
- RARE 2010
- VSEC 1959
- Country
- RARE United States
- VSEC United States
- Employees
- RARE N/A
- VSEC N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- VSEC Military/Government/Technical
- Sector
- RARE Health Care
- VSEC Consumer Discretionary
- Exchange
- RARE Nasdaq
- VSEC Nasdaq
- Market Cap
- RARE 3.1B
- VSEC 3.4B
- IPO Year
- RARE 2014
- VSEC N/A
- Fundamental
- Price
- RARE $33.28
- VSEC $170.04
- Analyst Decision
- RARE Strong Buy
- VSEC Strong Buy
- Analyst Count
- RARE 13
- VSEC 5
- Target Price
- RARE $87.69
- VSEC $171.00
- AVG Volume (30 Days)
- RARE 1.5M
- VSEC 147.0K
- Earning Date
- RARE 11-03-2025
- VSEC 10-28-2025
- Dividend Yield
- RARE N/A
- VSEC 0.24%
- EPS Growth
- RARE N/A
- VSEC 31.62
- EPS
- RARE N/A
- VSEC 0.95
- Revenue
- RARE $610,159,000.00
- VSEC $1,253,105,000.00
- Revenue This Year
- RARE $19.72
- VSEC $2.95
- Revenue Next Year
- RARE $23.29
- VSEC $13.76
- P/E Ratio
- RARE N/A
- VSEC $179.41
- Revenue Growth
- RARE 26.77
- VSEC 52.47
- 52 Week Low
- RARE $25.81
- VSEC $88.69
- 52 Week High
- RARE $56.38
- VSEC $174.56
- Technical
- Relative Strength Index (RSI)
- RARE 58.42
- VSEC 60.13
- Support Level
- RARE $32.40
- VSEC $155.59
- Resistance Level
- RARE $34.78
- VSEC $162.47
- Average True Range (ATR)
- RARE 1.26
- VSEC 5.30
- MACD
- RARE 0.27
- VSEC 0.88
- Stochastic Oscillator
- RARE 71.21
- VSEC 91.40
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About VSEC VSE Corporation
VSE Corp is a diversified aftermarket products and services company providing repair services, parts distribution, logistics, supply chain management, and consulting services for land, sea, and air transportation assets to commercial and government markets. Its operations include supply chain management solutions, parts supply and distribution, and maintenance, repair, and overhaul (MRO) services for vehicle fleet, aviation, maritime and other customers. Its reportable segments are; Aviation and Fleet. The majority of the revenue for the company is generated from the Aviation segment which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.